- Cancer supportive care products, offering essential relief and management for side effects arising from cancer treatments like chemotherapy and radiotherapy, are increasingly vital components of comprehensive oncology care in the MEA region due to their crucial role in enhancing patient well-being, treatment adherence, and overall quality of life.
- The fluctuating demand for these products is primarily driven by the continuous rise in cancer cases, the persistent need to mitigate severe treatment side effects, and a growing emphasis on holistic patient care that extends beyond tumor-directed therapy.
- While specific regional dominance data for MEA within the global market is not consistently available, the region is characterized by varying levels of healthcare development, with countries like Saudi Arabia, UAE, and Qatar showing advancements in healthcare systems, which are expected to increase demand for supportive care products. However, some African countries face challenges with adequate healthcare infrastructure, though initiatives with WHO and other organizations are working to improve this.
- The Antiemetics segment dominates the MEA cancer supportive care products market with a market share of 27.1% in 2024, driven by the high prevalence of chemotherapy-induced nausea and vomiting (CINV) and their critical role in patient comfort and treatment completion.
